SCHEMBL1811355

SCHEMBL1811355

CCOC(=O)c1cnc(CC(=O)S)nc1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.49
NPSR1 Q6W5P4 1/20 0.49
NPC1 O15118 4/20 0.48
MAPT P10636 3/20 0.48
HSP90AA1 P07900 1/20 0.45
KDM4E B2RXH2 3/20 0.44
SMN1; SMN2 Q16637 4/20 0.43
NFKB1 P19838 2/20 0.43
NFKB2 Q00653 2/20 0.43
RELA Q04206 2/20 0.43
ALDH1A1 P00352 5/20 0.43
PKM P14618 1/20 0.43
LMNA P02545 1/20 0.43
MAPK1 P28482 1/20 0.43
ATM Q13315 1/20 0.43
TSHR P16473 2/20 0.42
TP53 P04637 1/20 0.42
MEN1 O00255 1/20 0.42
GAA P10253 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1811356 0.84 RAB9A (0.51) RAB9ANPSR1NPC1MAPTHSP90AA1
SCHEMBL1810228 0.82 KDM4E (0.64) NPSR1MAPTHSP90AA1KDM4ESMN1; SMN2
SCHEMBL27875880 0.78 RAB9A (0.53) RAB9ANPSR1NPC1MAPTHSP90AA1
SCHEMBL4769593 0.78 MAPT (0.56) RAB9ANPSR1NPC1MAPTHSP90AA1
SCHEMBL26477898 0.78 RAB9A (0.51) RAB9ANPSR1NPC1MAPTHSP90AA1
SCHEMBL30996914 0.78 RAB9A (0.56) RAB9ANPSR1NPC1MAPTHSP90AA1
SCHEMBL1669574 0.78 RAB9A (0.56) RAB9ANPSR1NPC1MAPTHSP90AA1
SCHEMBL4752356 0.77 RAB9A (0.47) RAB9ANPSR1NPC1MAPTHSP90AA1
SCHEMBL4592965 0.76 RAB9A (0.55) RAB9ANPSR1NPC1MAPTHSP90AA1
SCHEMBL1143375 0.76 HSP90AA1 (0.70) RAB9ANPSR1NPC1MAPTHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1801108-B9 MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS MITSUBISHI TANABE PHARMA CORP (JP) 2013-11-20 EP disclosed
EP-1801108-B1 MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS MITSUBISHI TANABE PHARMA CORP (JP) 2012-11-14 EP disclosed
US-7935700-B2 Morpholine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-03 US disclosed
US-20070265257-A1 Morpholine Compound MITSUBISHI PHARMA CORPORATION (JP) 2007-11-15 US disclosed
EP-1801108-A1 MORPHOLINE COMPOUND Mitsubishi Pharma Corporation (JP) 2007-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265257-A1 Morpholine Compound CCR3, CCR1, CCR4 RAB9A 2642/4885NPSR1 1724/4885NPC1 668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.